Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

566 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Benefit from anthracyclines in relation to biological profiles in early breast cancer.
Rocca A, Bravaccini S, Scarpi E, Mangia A, Petroni S, Puccetti M, Medri L, Serra L, Ricci M, Cerasoli S, Biglia N, Maltoni R, Giunchi DC, Gianni L, Tienghi A, Brandi M, Faedi M, Sismondi P, Paradiso A, Silvestrini R, Amadori D. Rocca A, et al. Breast Cancer Res Treat. 2014 Apr;144(2):307-18. doi: 10.1007/s10549-013-2819-0. Epub 2014 Jan 1. Breast Cancer Res Treat. 2014. PMID: 24381054 Clinical Trial.
Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer.
Amadori D, Silvestrini R, De Lena M, Boccardo F, Rocca A, Scarpi E, Schittulli F, Brandi M, Maltoni R, Serra P, Ponzone R, Biglia N, Gianni L, Tienghi A, Valerio MR, Bonginelli P, Amaducci L, Faedi M, Baldini E, Paradiso A. Amadori D, et al. Among authors: rocca a. Breast Cancer Res Treat. 2011 Feb;125(3):775-84. doi: 10.1007/s10549-010-1257-5. Epub 2010 Dec 4. Breast Cancer Res Treat. 2011. PMID: 21132360 Free article. Clinical Trial.
Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer.
Farolfi A, Scarpi E, Rocca A, Mangia A, Biglia N, Gianni L, Tienghi A, Valerio MR, Gasparini G, Amaducci L, Faedi M, Baldini E, Rubagotti A, Maltoni R, Paradiso A, Amadori D. Farolfi A, et al. Among authors: rocca a. Eur J Cancer. 2015 Sep;51(14):1874-81. doi: 10.1016/j.ejca.2015.07.003. Epub 2015 Jul 20. Eur J Cancer. 2015. PMID: 26206258 Clinical Trial.
Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy.
Gennari A, Amadori D, Scarpi E, Farolfi A, Paradiso A, Mangia A, Biglia N, Gianni L, Tienghi A, Rocca A, Maltoni R, Antonucci G, Bruzzi P, Nanni O. Gennari A, et al. Among authors: rocca a. Breast Cancer Res Treat. 2016 Aug;159(1):79-86. doi: 10.1007/s10549-016-3923-8. Epub 2016 Jul 26. Breast Cancer Res Treat. 2016. PMID: 27460638 Clinical Trial.
Sorafenib for the treatment of breast cancer.
Bronte G, Andreis D, Bravaccini S, Maltoni R, Cecconetto L, Schirone A, Farolfi A, Fedeli A, Serra P, Donati C, Amadori D, Rocca A. Bronte G, et al. Among authors: rocca a. Expert Opin Pharmacother. 2017 Apr;18(6):621-630. doi: 10.1080/14656566.2017.1309024. Epub 2017 Apr 7. Expert Opin Pharmacother. 2017. PMID: 28335647 Review.
566 results